SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT ID: NCT00026260

Last Updated: 2013-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2003-10-31

Brief Summary

RATIONALE: Biological therapy with drugs such as SU5416 may stop the growth of cervical cancer by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have persistent or recurrent cervical cancer.

Detailed Description

OBJECTIVES:

• Determine the antitumor cytostatic activity of SU5416, in terms of 6-month progression-free survival and time to progression, in patients with persistent or recurrent cervical squamous cell carcinoma.
• Determine the nature and degree of toxicity of this drug in these patients.
• Correlate surrogate endpoint molecular and imaging markers with clinical outcome in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive SU5416 IV over 1 hour on days 1 and 4. Treatment repeats weekly in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study within 8-23 months.

Conditions

Cervical Cancer

Study Design

• Primary Study Purpose: TREATMENT

Interventions

semaxanib

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Tumor must be accessible for biopsy using direct- or guided-needle technique

PATIENT CHARACTERISTICS:

Age:

• Not specified

Performance status:

• GOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Platelet count at least lower limit of normal
• Absolute neutrophil count at least 1,500/mm^3

Hepatic:

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT no greater than 2.5 times ULN
• Alkaline phosphatase no greater than 2.5 times ULN

Renal:

• Creatinine no greater than 1.5 times ULN OR
• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• No uncompensated coronary artery disease on electrocardiogram or physical examination
• No myocardial infarction within the past 6 months
• No severe/unstable angina within the past 6 months
• No severe peripheral vascular disease
• No deep vein or arterial thrombosis within the past 3 months

Pulmonary:

• No pulmonary embolism within the past 3 months

Other:

• Not pregnant or nursing
• Fertile patients must use effective contraception
• Must have central venous access
• No uncontrolled diabetes mellitus
• No prior allergic reaction to paclitaxel
• No active infection requiring antibiotics
• No peripheral neuropathy greater than grade 1
• No contraindications to low-dose (1 mg/day) warfarin or low-molecular weight heparin prophylaxis
• No claustrophobia that would preclude MRI studies
• No ferromagnetic implants or pacers
• No other invasive malignancy within the past 5 years except non-melanoma skin cancer
• No other concurrent circumstances that would preclude study completion

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Biologic therapy:

• No prior antiangiogenesis agents, including SU5416
• At least 3 weeks since prior biologic or immunologic agents directed at malignancy

Chemotherapy:

• No more than 1 prior chemotherapy regimen, including single or combination cytotoxic drug therapy (radiosensitizers do not count as prior regimen)
• At least 3 weeks since prior chemotherapy directed at malignancy and recovered

Endocrine therapy:

• At least 1 week since prior hormonal therapy directed at malignancy
• Concurrent hormone replacement therapy allowed

Radiotherapy:

• At least 3 weeks since prior radiotherapy directed at malignancy and recovered

Surgery:

• See Disease Characteristics
• At least 3 weeks since prior surgery for malignancy and recovered

Other:

• No prior cancer therapy that would preclude study

• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Gynecologic Oncology Group

NETWORK

Sponsor Role: lead

Principal Investigators

Robert A. Burger, MD

Role: STUDY_CHAIR

Chao Family Comprehensive Cancer Center

Other Identifiers

GOG-0227B

Identifier Type: -

Identifier Source: secondary_id

CDR0000069013

Identifier Type: -

Identifier Source: org_study_id